Clinical Trial Update: Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease [Phase 4]

View source ↗

Summary

A Phase 4 parallel-group trial evaluating the effect of rasagiline on cognition in patients with Parkinson's disease has been completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• RASAGILINE (rasagiline)

Snippet

Sponsor: Teva Branded Pharmaceutical Products R&D, Inc. | Conditions: Parkinson's Disease | Phase 4 | Status: COMPLETED | Results posted: 2016-03-21